CMCandace D. McNaughton

Candace D. McNaughton

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Candace D. McNaughton has a total of 223 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Echocardiogram Testing in Patients with Post-COVID-19 Condition: A Systematic Review and Meta-Analysis

    by Jana Khawandi, Ali Choaib, Muayad Azzam, Gavin Y. Oudit, Khushi Patel, Jamil Nazzal, Aseel Al Khader, Hassan Kawtharany, Mohammad Amin Al Zabibi, Jood Ahmad, et al.

    Background: Post-COVID-19 condition (PCC) is a complication following acute COVID-19 infection, which may lead to long-term cardiac abnormalities. This review aimed to assess the prevalence of structural/functional deviations in echocardiography in individuals with PCC compared to patients without PCC. Methods: We searched three databases. Two reviewers independently screened articles using LASER Al and extracted relevant data using a piloted Excel sheet. We performed meta-analysis using OpenMeta and RevManWeb and a subgroup analysis based on patients’ settings during acute COVID-19. We assessed the risk of bias using the Hoy et al. tool and the certainty using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Results: We included 16 studies that reported on differences in echocardiographic findings in patients with or without PCC. Individuals with PCC were more likely to have structural/functional deviations in echocardiographic readings of unclear clinical significance, particularly those who were hospitalized during acute COVID-19. The overall certainty of the evidence was very low due to the high risk of bias, indirectness, and imprecision. Conclusions: This review provides insight into the use of echocardiograms and the frequency of test deviations in individuals with PCC. Despite existing evidence, there is a need for future studies to assess the diagnostic test accuracy of echocardiograms in PCC.

  • Open Access

    Modification of the Association of B-Type Natriuretic Peptides With Mortality and Hospitalization Outcomes by Sex

    by David Bobrowski, Husam Abdel-Qadir, Candace D. McNaughton, Anna Chu, Xuesong Wang, Peter C. Austin, Barbara S. Doumouras, Karem Abdul-Samad, Peter A. Kavsak, Michael E. Farkouh, et al.


  • Open Access

    Incident prescriptions for common cardiovascular medications: comparison of recent versus pre-2020 medication adherence and discontinuation in three universal health care systems

    by Candace D. McNaughton, Peter C. Austin, Cynthia A. Jackevicius, Anna Chu, Jessalyn K. Holodinsky, Michael D. Hill, Colleen M. Norris, Mukesh Kumar, Noreen Kamal, Douglas S. Lee, et al.

    Background: Health system disruptions since onset of the COVID-19 pandemic may have adversely impacted adherence to medications for common cardiovascular risk factors. Methods: We examined adherence to and discontinuation of incident prescriptions for medications treating hypertension, dyslipidemia, diabetes, and atrial fibrillation in Ontario, Alberta, and Nova Scotia, Canada. We compared the recent period (April 1, 2020 through most recently available follow-up: September 30, 2021 for Ontario; March 31, 2021 for Alberta; and March 31, 2022 for Nova Scotia) to the baseline, pre-pandemic period (April 1, 2014 through March 31, 2019). In each province, people aged ≥66 years with a valid health number and corresponding incident prescription were included. For each medication class, adherence in the recent period, defined as ≥ 0.80 proportion-of-days-covered (PDC), was compared to the pre-pandemic period using modified Poisson regression with robust error variance, adjusted for patient characteristics. Similarly adjusted Cox proportional hazards models compared hazard of discontinuation over one year of follow-up between the two time periods. Results: In the recent period, PDC ranged from 48.9% for dyslipidemia medications in Alberta to 82.2% for anticoagulants in Nova Scotia. Adherence was not different between periods, with the following exceptions: higher adherence in the recent period for antihypertensives (adjusted risk ratios [aRR] 1.08, 95% CI 1.06–1.10) and dyslipidemics (aRR 1.07, 95% CI 1.04–1.09) in Nova Scotia, and for antihyperglycemics (aRR 1.10, 95% CI 1.08–1.14) and anticoagulants (1.15, 95% CI 1.12, 1.18) in Alberta. Adherence was lower in the recent period only for antihypertensives in Alberta (aRR 0.95, 95% CI 0.93, 0.97). One-year rates of discontinuation ranged from 20.9% for anticoagulants in the Alberta recent period to 56.7% for antihypertensives in the Ontario baseline period. The adjusted hazard of discontinuation was lower or unchanged in the recent period for all medication classes. Conclusions: Despite significant health system disruptions since 2020, recent adherence to incident cardiovascular prescriptions was similar or better than before and rates of medication discontinuation were lower. However, interventions are still needed to improve existing, suboptimal adherence.


  • Open Access

    Turbulence in the system: Higher rates of left‐without‐being‐seen emergency department visits and associations with increased risks of adverse patient outcomes since 2020

    by Candace D. McNaughton, Peter C. Austin, Anna Chu, Maria Santiago‐Jimenez, Emily Li, Jessalyn K. Holodinsky, Noreen Kamal, Mukesh Kumar, Clare L. Atzema, Manav V. Vyas, et al.


  • Open Access

    Streptococcus pneumoniae Serotype Distribution Among US Adults Hospitalized With Community-Acquired Pneumonia, 2019–2020

    by Julio A Ramirez, Robin A Hubler, Mohammad Ali, Sharon L Gray, Ruth Carrico, Candace D McNaughton, Richard G Wunderink, Charles S Dela Cruz, Erica L Chilson, Alejandro D Cané, et al.

    Background: Serotype-specific urinary antigen detection (UAD) assay results can be used to estimate the serotype contribution among adults with pneumococcal community-acquired pneumonia (CAP) and to guide recommendations regarding higher-valency pneumococcal conjugate vaccines (PCVs). Methods: Adults aged ≥18 years hospitalized with radiographic evidence of CAP were prospectively enrolled in 4 US cities from November 2019 to December 2020, overlapping the coronavirus disease 2019 (COVID-19) pandemic. Data were collected by patient interview and medical chart review. Streptococcus pneumoniae was isolated from standard-of-care respiratory samples and blood; urine collected per-protocol was tested by S pneumoniae BinaxNOW and UAD assays. The proportions of adults with radiologically confirmed CAP (RAD+ CAP) testing positive for S pneumoniae and for serotypes contained in PCV13, PCV15, and PCV20 were calculated. Results: Among 3098 adults enrolled, 2105 (67.9%) had RAD+ CAP. Of these, 44.3% were ≥65 years of age, and most had a chronic medical condition (46.0%) or were immunocompromised (38.5%). Streptococcus pneumoniae was detected by any method in 214 (10.2%) RAD+ CAP participants, including 63 (3.0%) with serotypes covered by PCV13, 81 (3.9%) by PCV15, and 119 (5.7%) by PCV20. Streptococcus pneumoniae and PCV serotype positivity were higher before the pandemic (November 2019–April 2020) compared to during the COVID-19 pandemic (May 2020–December 2020). Conclusions: Our study demonstrated that despite the COVID-19 pandemic, PCV serotype pneumococcus continued to cause an important proportion of adult CAP in the US. These data are useful for informing PCV recommendations and for establishing an epidemiologic baseline to assess the impact of such recommendations.


  • Open Access

    Higher Post-Acute Health Care Costs Following SARS-CoV-2 Infection Among Adults in Ontario, Canada

    by Candace D McNaughton, Peter C Austin, Zhiyin Li, Atul Sivaswamy, Jiming Fang, Husam Abdel-Qadir, Jacob Udell, Walter P Wodchis, Douglas S Lee, Ivona Mostarac, et al.

    Purpose and Introduction: Growing evidence suggests SARS-CoV-2 infection increases the risk of long term cardiovascular, neurological, and other effects. However, post-acute health care costs following SARS-CoV-2 infection are not known. Patients and Statistical Methods: Beginning 56 days following SARS-CoV-2 polymerase chain reaction (PCR) testing, we compared person-specific total and component health care costs (2020 CAD$) for the first year of follow-up at the mean and 99th percentiles of health care costs for matched test-positive and test-negative adults in Ontario, Canada, between January 1, 2020, and March 31, 2021. Matching included demographics, baseline clinical characteristics, and two-week time blocks. Results: For 531,182 people, mean person-specific total health care costs were $513.83 (95% CI $387.37-$638.40) higher for test-positive females and $459.10 (95% CI $304.60-$615.32) higher for test-positive males, which were driven by hospitalization, long-term care, and complex continuing care costs. At the 99th percentile of each subgroup, person-specific health care costs were $12,533.00 (95% CI $9008.50-$16,473.00) higher for test-positive females and $14,604.00 (95% CI $9565.50-$19,506.50) for test-positive males, driven by hospitalization, specialist (males), and homecare costs (females). Cancer costs were lower. Six-month and 1-year cost differences were similar. Conclusion: Post-acute health care costs after a positive SARS-CoV-2 PCR test were significantly higher than matched test-negative individuals, and these increased costs persisted for at least one year. The largest increases health care costs came from hospitalizations, long-term care, complex continuing care, followed by outpatient specialists (for males) and homecare costs (for women). Given the magnitude of ongoing viral spread, policymakers, clinicians, and patients should be aware of higher post-acute health care costs following SARS-CoV-2 infection. Plain Language Summary: We examined differences in health care costs for people who had a positive PCR for SARS-CoV-2 in Ontario, Canada, starting 56 days after the positive test at looking forward at least 1 year, matched by > 20 characteristics to people with a negative PCR within two weeks. During the study, the average health care costs per person were approximately $4800 (2020 CAD$). We found that on average, health care costs were $513.83 higher (2020 CAD$; +11% higher than average health care costs) for women who had a positive PCR test and $459.10 higher (+10% higher than average health care costs) for men who had a positive PCR test. Most of the increased costs were due to hospitalization, long-term care, and complex continuing care costs. When we looked at people who had the highest health care costs (the 99th percentile), health care costs for women with a positive PCR test were $12,533.00 higher (+261% higher than average health care costs) and $14,604.00 higher for men (+304% higher than average health care costs), with higher costs driven by hospitalization, specialist (males), and homecare costs (females). Cancer costs were lower for people with a positive test. In summary, post-acute health care costs were higher for people who had a positive SARS-CoV-2 PCR test, after accounting for multiple patient-level factors. Higher costs persisted for a least one year of follow-up.


  • Open Access

    Correction: The Effect of an mHealth Self-Monitoring Intervention (MI-BP) on Blood Pressure Among Black Individuals With Uncontrolled Hypertension: Randomized Controlled Trial

    by Lorraine R Buis, Junhan Kim, Ananda Sen, Dongru Chen, Katee Dawood, Reema Kadri, Rachelle Muladore, Melissa Plegue, Caroline R Richardson, Zora Djuric, et al.

    [This corrects the article DOI: 10.2196/57863.].


  • Open Access

    Correction: The Effect of an mHealth Self-Monitoring Intervention (MI-BP) on Blood Pressure Among Black Individuals With Uncontrolled Hypertension: Randomized Controlled Trial (Preprint)

    by Lorraine R Buis, Junhan Kim, Ananda Sen, Dongru Chen, Katee Dawood, Reema Kadri, Rachelle Muladore, Melissa Plegue, Caroline R Richardson, Zora Djuric, et al.

    Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).

  • Open Access

    The Effect of an mHealth Self-Monitoring Intervention (MI-BP) on Blood Pressure Among Black Individuals With Uncontrolled Hypertension: Randomized Controlled Trial

    by Lorraine R Buis, Junhan Kim, Ananda Sen, Dongru Chen, Katee Dawood, Reema Kadri, Rachelle Muladore, Melissa Plegue, Caroline R Richardson, Zora Djuric, et al.

    Background: Hypertension is one of the most important cardiovascular disease risk factors and affects >100 million American adults. Hypertension-related health inequities are abundant in Black communities as Black individuals are more likely to use the emergency department (ED) for chronic disease–related ambulatory care, which is strongly linked to lower blood pressure (BP) control, diminished awareness of hypertension, and adverse cardiovascular events. To reduce hypertension-related health disparities, we developed MI-BP, a culturally tailored multibehavior mobile health intervention that targeted behaviors of BP self-monitoring, physical activity, sodium intake, and medication adherence in Black individuals with uncontrolled hypertension recruited from ED and community-based settings. Objective: We sought to determine the effect of MI-BP on BP as well as secondary outcomes of physical activity, sodium intake, medication adherence, and BP control compared to enhanced usual care control at 1-year follow-up. Methods: We conducted a 1-year, 2-group randomized controlled trial of the MI-BP intervention compared to an enhanced usual care control group where participants aged 25 to 70 years received a BP cuff and hypertension-related educational materials. Participants were recruited from EDs and other community-based settings in Detroit, Michigan, where they were screened for initial eligibility and enrolled. Baseline data collection and randomization occurred approximately 2 and 4 weeks after enrollment to ensure that participants had uncontrolled hypertension and were willing to take part. Data collection visits occurred at 13, 26, 39, and 52 weeks. Outcomes of interest included BP (primary outcome) and physical activity, sodium intake, medication adherence, and BP control (secondary outcomes). Results: We obtained consent from and enrolled 869 participants in this study yet ultimately randomized 162 (18.6%) participants. At 1 year, compared to the baseline, both groups showed significant decreases in systolic BP (MI-BP group: 22.5 mm Hg decrease in average systolic BP and P<.001; control group: 24.1 mm Hg decrease and P<.001) adjusted for age and sex, with no significant differences between the groups (time-by-arm interaction: P=.99). Similar patterns where improvements were noted in both groups yet no differences were found between the groups were observed for diastolic BP, physical activity, sodium intake, medication adherence, and BP control. Large dropout rates were observed in both groups (approximately 60%). Conclusions: Overall, participants randomized to both the enhanced usual care control and MI-BP conditions experienced significant improvements in BP and other outcomes; however, differences between groups were not detected, speaking to the general benefit of proactive outreach and engagement focused on cardiometabolic risk reduction in urban-dwelling, low-socioeconomic-status Black populations. High dropout rates were found and are likely to be expected when working with similar populations. Future work is needed to better understand engagement with mobile health interventions, particularly in this population. Trial Registration: ClinicalTrials.gov NCT02955537; https://clinicaltrials.gov/study/NCT02955537 International Registered Report Identifier (IRRID): RR2-10.2196/12601


  • Open Access

    Population Trends of New Prescriptions for Antihyperglycemics and Antihypertensives Between 2014 and 2022

    by Amy Y. X. Yu, Peter C. Austin, Cynthia A. Jackevicius, Anna Chu, Jessalyn K. Holodinsky, Michael D. Hill, Noreen Kamal, Mukesh Kumar, Douglas S. Lee, Manav V. Vyas, et al.

    Background: In the wake of pandemic‐related health decline and health care disruptions, there are concerns that previous gains for cardiovascular risk factors may have stalled or reversed. Population‐level excess burden of drug‐treated diabetes and hypertension during the pandemic compared with baseline is not well characterized. We evaluated the change in incident prescription claims for antihyperglycemics and antihypertensives before versus during the pandemic. Methods and Results: In this retrospective, serial, cross‐sectional, population‐based study, we used interrupted time series analyses to examine changes in the age‐ and sex‐standardized monthly rate of incident prescriptions for antihyperglycemics and antihypertensives in patients aged ≥66 years in Ontario, Canada, before the pandemic (April 2014 to March 2020) compared with during the pandemic (July 2020 to November 2022). Incident claim was defined as the first prescription filled for any medication in these classes. The characteristics of patients with incident prescriptions of antihyperglycemics (n=151 888) or antihypertensives (n=368 123) before the pandemic were comparable with their pandemic counterparts (antihyperglycemics, n=97 015; antihypertensives, n=146 524). Before the pandemic, monthly rates of incident prescriptions were decreasing (−0.03 per 10 000 individuals [95% CI, −0.04 to −0.01] for antihyperglycemics; −0.14 [95% CI, −0.18 to −0.10] for antihypertensives). After July 2020, monthly rates increased (postinterruption trend 0.31 per 10 000 individuals [95% CI, 0.28–0.34] for antihyperglycemics; 0.19 [95% CI, 0.14–0.23] for antihypertensives). Conclusions: Population‐level increases in new antihyperglycemic and antihypertensive prescriptions during the pandemic reversed prepandemic declines and were sustained for >2 years. Our findings are concerning for current and future cardiovascular health.